EARLY VEDOLIZUMAB TROUGH LEVELS ARE NOT ASSOCIATED WITH A SHORT-TERM RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

被引：0
|
作者：
Pudilova, Karolina
Duricova, Dana
Kolar, Martin
Malickova, Karin
Hruba, Veronika
Machkova, Nadezda
Vanickova, Radka
Mitrova, Katarina
Lukas, Martin
Vasatko, Martin
Lukas, Milan
Bortlik, Martin
机构：
来源：
GASTROENTEROLOGY | 2019年 / 156卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Mo1894
引用
收藏
页码：S877 / S877
页数：1
相关论文
共 50 条
  • [1] Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease
    Pudilova, K.
    Kolar, M.
    Duricova, D.
    Malickova, K.
    Hruba, V.
    Machkova, N.
    Vanickova, R.
    Mitrova, K.
    Lukas, M.
    Vasatko, M.
    Lukas, M.
    Bortlik, M.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S356 - S356
  • [2] Vedolizumab trough concentrations are associated with endoscopic response in patients with inflammatory bowel disease
    Chao, C. -Y.
    Restellini, S.
    Lemieux, C.
    Germain, P.
    Bitton, A.
    Lakatos, P. L.
    Wild, G.
    Seidman, E.
    Bessissow, T.
    Afif, W.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S367 - S368
  • [3] Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease
    Yacoub, W.
    Williet, N.
    Pouillon, L.
    Di-Bernado, T.
    Bittencourt, M. De Carvalho
    Nancey, S.
    Lopez, A.
    Paul, S.
    Zallot, C.
    Roblin, X.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S334 - S334
  • [4] EARLY VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL RESPONSE IN A "REAL WORLD" PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
    Bonthala, Nirupama
    Morganstern, Bradley
    Mengesha, Emebet
    Landers, Carol
    Mould, Diane R.
    Li, Dalin
    Vasiliauskas, Eric
    Targan, Stephan R.
    McGovern, Dermot P. B.
    Melmed, Gil
    GASTROENTEROLOGY, 2020, 158 (06) : S465 - S466
  • [5] Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance
    Liefferinckx, Claire
    Minsart, Charlotte
    Cremer, Anneline
    Amininejad, Leila
    Tafciu, Vjola
    Quertinmont, Eric
    Tops, Sophie
    Deviere, Jacques
    Gils, Ann
    van Gossum, Andre
    Franchimont, Denis
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (04) : 478 - 485
  • [6] VEDOLIZUMAB TROUGH LEVELS AND CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE
    Guidi, L.
    Pugliese, D.
    Tonucci, T. Panici
    Tolusso, B.
    Felice, C.
    Papa, A.
    Ennas, S.
    Di Mario, C.
    Gasbarrini, A.
    Rapaccini, G. L.
    Armuzzi, A.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E99 - E100
  • [7] CLINICAL EXPERIENCE WITH VEDOLIZUMAB TROUGH LEVELS IN INFLAMMATORY BOWEL DISEASE
    Al-Bawardy, Badr
    Ramos, Guilherme Piovezani
    Willrich, Maria Alice V.
    Park, Sang Hyoung
    Aniwan, Satimai
    Raffals, Laura H.
    Tremaine, William J.
    Loftus, Edward V.
    GASTROENTEROLOGY, 2018, 154 (06) : S821 - S822
  • [8] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [9] Ustekinumab Trough Levels are not Associated with Clinical Response in Inflammatory Bowel Disease Patients
    Zelinkova, Z.
    Lipovska, A.
    Otottova, K.
    Lucenicova, J.
    Kadleckova, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S460 - S461
  • [10] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
12345